

Karolinska Development publishes prospectus relating to set-off issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

STOCKHOLM - March 17, 2017. Karolinska Development AB's (publ) ("Karolinska Development" or the "Company") prospectus relating to a new issue of B-shares to the Company's convertible holders, with payment by set-off (the "Set-off Issue") was approved by and registered with the Swedish Financial Supervisory Authority on March 16, 2017.

The prospectus relating to Karolinska Development's Set-off Issue is now available at the Company's website (www.karolinskadevelopment.com) and the SEB Emissioner's website (www.sebgroup.se/prospectuses).

Karolinska Development has retained Advokatfirman Lindahl as legal adviser in connection with the Set-off Issue. SEB Emissioner acts as issuing agent in connection with the Set-off Issue.

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB

Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB

Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The Company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com.

Important information

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities in Karolinska Development. Any invitation to the persons concerned to subscribe for shares in Karolinska Development will only be made through the prospectus referred to in this press release.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, New Zealand, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to those required under Swedish laws and regulations. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No shares have been or will be registered under the U.S. Securities Act of 1933, as amended ("Securities Act"), or securities legislation in any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, in or into the United States, except pursuant to an available exemption from the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.

This press release may contain forward-looking statements which reflect Karolinska Development's current view on future events and financial and operational development. The words "intend", "estimate", "expect", "may", "plan", "anticipate" or similar expressions regarding indications or predictions of future developments or trends and which are not statements based on historical facts constitute forward-looking information. Although Karolinska Development believes that these statements are based on reasonable assumptions and expectations, Karolinska Development cannot give any assurances that such statements will materialize. Forward-looking statements are in its nature involved with both known and unknown risks and uncertainties, since it is depending on future events and circumstances. Forward-looking statements do not constitute any representations and warranties, and the outcome could differ materially from the information set out in the forward-looking statements.

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obligated to make public pursuant to the Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of Jim Van heusden, on March 17, 2017 at 08:00 (CET).